I2PETPG - Quantification and Localisation of Imidazoline2 Binding Sites in a Group of Participants Diagnosed With Alzheimer's Disease Using 11C‑BU99008: a Positron Emission Tomography Study

Trial Profile

I2PETPG - Quantification and Localisation of Imidazoline2 Binding Sites in a Group of Participants Diagnosed With Alzheimer's Disease Using 11C‑BU99008: a Positron Emission Tomography Study

Completed
Phase of Trial: Phase 0

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs BU 99008 (Primary) ; Idazoxan (Primary)
  • Indications Alzheimer's disease
  • Focus Diagnostic use
  • Acronyms I2PETPG
  • Most Recent Events

    • 05 Mar 2018 Status changed from recruiting to completed.
    • 24 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top